P2Y12 inhibitors in cardiovascular disease: focus on prasugrel. - Wikidata - wikimedia - TriplyDB

P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.

P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.

http://www.wikidata.org/entity/Q37339517

about

Prasugrel metabolites inhibit neutrophil functions Thienopyridines in Acute Coronary Syndrome.P2Y12 platelet inhibition in clinical practice.P2Y₁₂ receptor inhibitors: integrating ticagrelor into the management of acute coronary syndrome.

P2860

Q36497588-DE9306AD-5B83-4B26-901B-B36F1763A9D5 Q37838124-A8E10B4C-9733-4CE6-962A-688A85A2EF95 Q37969927-9B99BE29-E172-4DF9-8BCE-47CAA9461DBE Q51539033-6A9D79E1-709E-4A37-B41C-0E9ED2715F64

P2860

P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.

http://www.wikidata.org/entity/Q37339517

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.

@en

P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.

@nl

type

label

P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.

@en

P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.

@nl

prefLabel

P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.

@en

P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.

@nl

P1433

Q37339517-A502AC44-005E-48D9-B9BB-60064C323652

P1476

Q37339517-8FBCC389-90D2-411B-9A44-6BC87D4035D1

P2093

Q37339517-7EEBC458-2E57-4055-A11F-CF878EDC9198

Q37339517-7FABC7F0-2BBF-4B88-9445-6BDE2D574634

Q37339517-8739B0DE-FD7D-4791-8D34-6F9DE9315541

P2860

Q37339517-08EE0C03-998E-4795-BDB3-12F8A56C0081

Q37339517-10F0D65B-BB35-4F25-BC40-F67495ECE843

Q37339517-144077BF-20BC-4D9E-870C-4060AC357922

Q37339517-2D8B1F6B-CC4A-4C47-B3AC-E1E6F03CF951

Q37339517-2DA8BCDA-8B7C-4A16-9D4D-304D578A6811

Q37339517-35973368-3EFE-4FC0-88AA-E7F499AF1AF4

Q37339517-38CCDBF6-0D90-4058-B7B3-F45355D76741

Q37339517-3B09D504-594E-49C1-A58F-2A999707CB24

Q37339517-3E61AD27-F676-4197-B5D4-4B35D5B16971

Q37339517-422B1BB0-01B5-4233-9C15-4B9355A04288

P304

Q37339517-3F19F72C-F3E3-4827-8635-57BABEEF0903

P31

Q37339517-63190265-7406-4417-AA50-FA2649C931BA

P356

Q37339517-6D96D5AD-3F6F-4784-AAF4-209F3AD22480

P407

Q37339517-84C16CDA-5A07-464E-A372-392681F45DBA

P433

Q37339517-64965773-C4B8-4319-86C5-3A8AEAE3DC9A

P478

Q37339517-15B683E6-CFFE-462C-BCD7-5F7984F366B1

P577

Q37339517-842513BE-1DC1-4A8E-BAB8-8BAAA1B92443

P698

Q37339517-D08D4DD5-3589-4221-9203-3C41A8160E4E

P921

Q37339517-A8AE59F3-8A51-4DD5-8739-B7432A8A31BB

P356

P1433

Annals of Pharmacotherapy

P1476

P2Y12 inhibitors in cardiovascular disease: focus on prasugrel.

@en

P2093

David Parra

http://www.w3.org/2001/XMLSchema#string

Day Marice Scott

http://www.w3.org/2001/XMLSchema#string

Rhonda M Norwood

http://www.w3.org/2001/XMLSchema#string

P2860

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

Stent thrombosis is associated with an impaired response to antiplatelet therapy

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

P304

64-76

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1G726

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19050170

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease